KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $23.3 million.

  • Alnylam Pharmaceuticals' Capital Expenditures rose 15612.49% to $23.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $58.7 million, marking a year-over-year increase of 7124.31%. This contributed to the annual value of $58.7 million for FY2025, which is 7124.31% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Capital Expenditures of $23.3 million as of Q4 2025, which was up 15612.49% from $12.1 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Capital Expenditures high stood at $26.1 million for Q3 2021, and its period low was $4.2 million during Q3 2024.
  • For the 5-year period, Alnylam Pharmaceuticals' Capital Expenditures averaged around $15.2 million, with its median value being $15.6 million (2023).
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 7547.39% in 2024, then surged by 18964.69% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Capital Expenditures (Quarter) stood at $21.9 million in 2021, then fell by 1.15% to $21.6 million in 2022, then dropped by 29.24% to $15.3 million in 2023, then crashed by 40.6% to $9.1 million in 2024, then surged by 156.12% to $23.3 million in 2025.
  • Its Capital Expenditures stands at $23.3 million for Q4 2025, versus $12.1 million for Q3 2025 and $14.3 million for Q2 2025.